Legis Daily

Cancer Drug Parity Act of 2021

USA117th CongressHR-4385| House 
| Updated: 7/9/2021
Brian Higgins

Brian Higgins

Democratic Representative

New York

Cosponsors (36)
Dwight Evans (Democratic)Michael C. Burgess (Republican)Tom Malinowski (Democratic)Don Young (Republican)Brett Guthrie (Republican)David J. Trone (Democratic)Ed Case (Democratic)Emanuel Cleaver (Democratic)John A. Yarmuth (Democratic)Carolyn B. Maloney (Democratic)Robert J. Wittman (Republican)Pete Aguilar (Democratic)Jimmy Panetta (Democratic)Thomas R. Suozzi (Democratic)Alan S. Lowenthal (Democratic)Ann M. Kuster (Democratic)Gus M. Bilirakis (Republican)Joseph D. Morelle (Democratic)Rodney Davis (Republican)Doris O. Matsui (Democratic)Glenn Grothman (Republican)Lucy McBath (Democratic)Kathy Castor (Democratic)Jamie Raskin (Democratic)Mike Bost (Republican)Julia Brownley (Democratic)Yvette D. Clarke (Democratic)Brian K. Fitzpatrick (Republican)Colin Z. Allred (Democratic)Earl Blumenauer (Democratic)Suzanne Bonamici (Democratic)Nanette Diaz Barragán (Democratic)Gerald E. Connolly (Democratic)Chellie Pingree (Democratic)Grace F. Napolitano (Democratic)Susan Wild (Democratic)

Education and Workforce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Cancer Drug Parity Act of 20 21 This bill requires group health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration. To comply with this requirement, plans may not, with respect to anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-1730
Cancer Drug Parity Act of 2019
Jul 9, 2021
Introduced in House
Jul 9, 2021
Referred to the House Committee on Education and Labor.
Oct 27, 2021

Latest Companion Bill Action

S 117-3080
Introduced in Senate
  • Bill from Previous Congress

    HR 116-1730
    Cancer Drug Parity Act of 2019


  • July 9, 2021
    Introduced in House


  • July 9, 2021
    Referred to the House Committee on Education and Labor.


  • October 27, 2021

    Latest Companion Bill Action

    S 117-3080
    Introduced in Senate

Health

Related Bills

  • S 117-3080: Cancer Drug Parity Act of 2021

Cancer Drug Parity Act of 2021

USA117th CongressHR-4385| House 
| Updated: 7/9/2021
Cancer Drug Parity Act of 20 21 This bill requires group health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration. To comply with this requirement, plans may not, with respect to anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-1730
Cancer Drug Parity Act of 2019
Jul 9, 2021
Introduced in House
Jul 9, 2021
Referred to the House Committee on Education and Labor.
Oct 27, 2021

Latest Companion Bill Action

S 117-3080
Introduced in Senate
  • Bill from Previous Congress

    HR 116-1730
    Cancer Drug Parity Act of 2019


  • July 9, 2021
    Introduced in House


  • July 9, 2021
    Referred to the House Committee on Education and Labor.


  • October 27, 2021

    Latest Companion Bill Action

    S 117-3080
    Introduced in Senate
Brian Higgins

Brian Higgins

Democratic Representative

New York

Cosponsors (36)
Dwight Evans (Democratic)Michael C. Burgess (Republican)Tom Malinowski (Democratic)Don Young (Republican)Brett Guthrie (Republican)David J. Trone (Democratic)Ed Case (Democratic)Emanuel Cleaver (Democratic)John A. Yarmuth (Democratic)Carolyn B. Maloney (Democratic)Robert J. Wittman (Republican)Pete Aguilar (Democratic)Jimmy Panetta (Democratic)Thomas R. Suozzi (Democratic)Alan S. Lowenthal (Democratic)Ann M. Kuster (Democratic)Gus M. Bilirakis (Republican)Joseph D. Morelle (Democratic)Rodney Davis (Republican)Doris O. Matsui (Democratic)Glenn Grothman (Republican)Lucy McBath (Democratic)Kathy Castor (Democratic)Jamie Raskin (Democratic)Mike Bost (Republican)Julia Brownley (Democratic)Yvette D. Clarke (Democratic)Brian K. Fitzpatrick (Republican)Colin Z. Allred (Democratic)Earl Blumenauer (Democratic)Suzanne Bonamici (Democratic)Nanette Diaz Barragán (Democratic)Gerald E. Connolly (Democratic)Chellie Pingree (Democratic)Grace F. Napolitano (Democratic)Susan Wild (Democratic)

Education and Workforce Committee

Health

Related Bills

  • S 117-3080: Cancer Drug Parity Act of 2021
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted